Want to see GB:SBTX full AI Analyst Report?
SkinBioTherapeutics (SBTX) AI Stock Analysis
SkinBioTherapeutics
(LSE:SBTX)
The score is mainly driven by improving revenue growth and a solid balance sheet, which are offset by ongoing losses and negative cash flow. Technical momentum is supportive but near overbought levels, while valuation remains weak because earnings are still negative and no dividend support is present.
SkinBioTherapeutics (SBTX) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 13.61M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.02M
- Price to Earnings (P/E)
- -29.2
- Beta (1Y)
- 0.05
- Revenue Growth
- 95.16%
- EPS Growth
- 85.60%
- Country
- UK
- Employees
- 41
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
SkinBioTherapeutics Business Overview & Revenue Model
Company Description
SkinBioTherapeutics Plc is a life sciences enterprise dedicated to enhancing human health through the exploration and development of technologies that harness the power of the human microbiome. The company has developed two primary technological plat...
How the Company Makes Money
SkinBioTherapeutics primarily generates revenue by commercializing its skin-health technology and related ingredients via business-to-business arrangements. Key revenue streams include: (1) partnering with consumer brands or manufacturers to incorpor...
SkinBioTherapeutics Financial Statement Overview
Summary
Revenue growth and gross profit expansion are strong, and the balance sheet is low-leverage and well capitalized. However, persistent EBIT, net income, and free cash flow losses keep the overall financial profile below a high-growth quality level.
Income Statement
68PositiveBalance Sheet
72PositiveCash Flow
55Neutral| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.23M | 4.64M | 1.21M | 132.06K | 74.76K | 0 |
| Gross Profit | 2.95M | 2.71M | 683.04K | 85.19K | 45.34K | -5,055 |
| EBITDA | -99.28K | -196.54K | -2.72M | -2.96M | -2.95M | -1.49M |
| Net Income | -456.41K | -696.25K | -2.88M | -2.84M | -2.79M | -1.43M |
Balance Sheet | ||||||
| Total Assets | 9.60M | 12.13M | 5.22M | 2.59M | 3.08M | 5.73M |
| Cash, Cash Equivalents and Short-Term Investments | 3.12M | 4.78M | 800.90K | 1.31M | 1.80M | 4.61M |
| Total Debt | 939.16K | 993.47K | 818.74K | 100.65K | 127.86K | 139.85K |
| Total Liabilities | 1.63M | 2.71M | 2.25M | 599.34K | 609.61K | 519.67K |
| Stockholders Equity | 7.98M | 9.42M | 2.97M | 1.99M | 2.48M | 5.22M |
Cash Flow | ||||||
| Free Cash Flow | -2.05M | -1.30M | -2.92M | -2.81M | -2.77M | -1.67M |
| Operating Cash Flow | -2.02M | -1.30M | -2.73M | -2.65M | -2.67M | -1.56M |
| Investing Cash Flow | -177.13K | -1.62M | -2.30M | -165.28K | -96.81K | -112.31K |
| Financing Cash Flow | 4.09M | 6.90M | 4.51M | 2.32M | -35.12K | 4.12M |
SkinBioTherapeutics Peers Comparison
Overall Rating
- GB:SBTX59Neutral
GB:OBI44Neutral
GB:IMM43Neutral
GB:AREC41Neutral
GB:OPTI41Neutral
GB:APTA37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GB:SBTX | 59Neutral | GBP 13.61M | -29.17 | -5.25% | ― | 95.16% | 85.60% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:OBI | 44Neutral | GBP 64.47M | -2.70 | -9999.00% | ― | 26.99% | 4.36% |
| GB:IMM | 43Neutral | GBP 20.28M | -2.65 | -559.87% | ― | ― | 5.62% |
| GB:AREC | 41Neutral | GBP 37.37M | 165.00 | 3.75% | ― | ― | ― |
| GB:OPTI | 41Neutral | GBP 5.99M | -1.40 | -77.85% | ― | 11.90% | -2864.29% |
| GB:APTA | 37Underperform | GBP 10.23M | -9.50 | -46.61% | ― | 28.35% | 57.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:SBTX | SkinBioTherapeutics plc | 5.25 | -10.88 | -67.44% | |
| GB:IMM | ImmuPharma plc | 3.31 | -6.69 | -66.85% | |
| GB:OPTI | OptiBiotix Health | 5.80 | -1.95 | -25.16% | |
| GB:AREC | Arecor Therapeutics PLC | 82.50 | 10.00 | 13.79% | |
| GB:APTA | Aptamer Group Plc | 0.28 | -0.53 | -65.24% | |
| GB:OBI | Ondine Biomedical, Inc. | 9.30 | -3.70 | -28.46% |
SkinBioTherapeutics Corporate Events
SkinBioTherapeutics to Outline FRP Findings and Outlook in Investor Presentation
PositiveSkinBioTherapeutics, a life sciences business listed on AIM and headquartered in Newcastle, develops evidence-based topical and oral products to support skin health, repair, well-being and beauty, underpinned by its SkinBiotix platform. The company c...
SkinBioTherapeutics CFO to Depart as Group Installs Interim Finance Chief
NeutralSkinBioTherapeutics, the AIM-listed skin health-focused life sciences group, has announced the resignation of Chief Financial Officer Emily Bertram, who will leave the company on 30 June 2026 after playing a key role in financial stewardship and gove...
SkinBioTherapeutics to Host Investor Presentation to Deepen Shareholder Engagement
PositiveSkinBioTherapeutics, a life sciences company specialising in evidence-based skin health solutions and oral supplements, leverages its SkinBiotix technology platform and contract manufacturing capabilities to support skin well-being, repair and beauty...
SkinBioTherapeutics Restates FY25 Results as CEO Probe Uncovers Fabricated Revenue
NegativeSkinBioTherapeutics reported unaudited half-year revenues to 31 December 2025 up 37.4% to £2.17m, driven by a full six-month contribution from Bio-Tech Solutions, stable Dermatonics sales, AxisBiotix product launches in over 180 Superdrug stores...
SkinBioTherapeutics completes financial probe, delays results and appoints new auditor
NegativeSkinBioTherapeutics said its board has completed an investigation into its financial statements for the year to 30 June 2025 and expects to publish delayed interim HY26 results alongside restated, unaudited FY25 figures shortly. The company indicated...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jul 22, 2026